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oRIGINAL ARTICLE
Introduction: FHIT and p53 are the two most commonly altered 
tumor suppressor genes in lung cancer, and their molecular status 
regulates sensitivity to anticancer drugs. Although their functions are 
independent, there is evidence that their pathways might be intercon-
nected, but little is known at the molecular level.
Methods: Microarray profiling of FHIT-transduced lung can-
cer cells and modulation of FHIT levels by RNA interference in 
human bronchial cells were used to generate a signature of 
FHIT-regulated transcripts. Expression of these genes was evalu-
ated by real-time polymerase chain reaction in 55 primary lung 
cancer samples characterized for FHIT and p53 expression by 
immunohistochemistry.
Results: A signature of FHIT-regulated transcripts, particularly 
enriched in genes involved in cell cycle control, was identified. This 
signature showed overlap with p53-regulated genes, indicating pos-
sible crosstalk between these proteins. Consistently, transcriptional 
deregulation after FHIT modulation was higher in p53-negative cells. 
In primary lung cancers, inactivation of either gene was detected 
in 48 of 55 cases (87%) and both genes in 23 of 55 (42%) cases, 
confirming the central role of these pathways. Primary tumors with 
inactivation of both FHIT and p53 displayed the strongest deregula-
tion of growth-related pathways with high levels of expression of 
CCNB1, BUB1, CDC6, TOP2A, MCM6, and CENPF.
Conclusions: FHIT and p53 seem to rely on common mediators, 
and inactivation of both genes results in prominent deregulation 
of growth-related pathways in lung cancer cell lines and primary 
tumors. This reveals crosstalk between these proteins and suggests a 
possible distinctive phenotype for tumors with inactivation of both 
genes.
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(J Thorac Oncol. 2012;7: 631–642)
The malignant transformation of bronchial cells is a mul-tistep process driven by genetic and epigenetic molecular 
changes affecting oncogenes and tumor suppressor genes. 
Although many different alterations have been described, the 
contribution of individual changes to the malignant pheno-
type remains unclear. Among the most frequent alterations, 
chromosome 3p deletions have been often observed also in 
preneoplastic lesions, indicating an involvement of genes 
residing in this chromosomal area in the early phases of lung 
cancer development.1 The FHIT gene, located at 3p14.2, 
spans the FRA3B fragile site and is often inactivated in lung 
cancer and preinvasive bronchial lesions.2,3 Restoration of 
its expression in cancer cell lines has antiproliferative and 
proapoptotic activity,4,5 and many studies have reported its 
relevance in lung cancer, but the mechanism by which the 
FHIT protein controls proliferation and cell death is yet to be 
fully elucidated.6
In lung cancer cell lines, the antiproliferative effects 
of FHIT restoration are dose-dependent.7 Furthermore, it has 
recently been reported that a small and transient reduction of 
FHIT levels might allow the transmission of mitogenic sig-
nals through EGFR family members.8 Cells lacking FHIT 
expression have been shown to be resistant to genotoxic stress 
induced by UVC and mitomycin C9 and, at the molecular 
level, a role in DNA damage response was suggested with 
the demonstration of an involvement in the ATR/CHK1 path-
way10 with opposing effects for Fhit and Chk1 on homologous 
recombination repair.11 Taken together, these observations 
indicate a crucial function for FHIT in the fine-tuning of dif-
ferent processes including cell proliferation, apoptosis, and 
response to DNA damage.
A synergistic role for FHIT and p53 has also been pro-
posed, indicating that two of the most commonly altered genes 
in lung cancer may be interconnected12,13 and may also jointly 
control sensitivity to chemotherapy.14
Because the expression of FHIT and p53 is already 
altered in the preneoplastic lesion, and both genes are involved 
in DNA damage response and apoptosis pathways, it is 
tempting to speculate that their alteration might provide an 
environment conducive to the growth and proliferation of 
cancer cells.
Several studies of gene expression patterns modulated 
by p53 using microarray analysis are available,15,16 while few 
data about FHIT-regulated genes have been presented.17 To 
examine FHIT oncosuppressive properties at the molecular 
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level and to better understand the relationship between FHIT 
and p53 status, we investigated the modifications in the tran-
scriptional profile induced by adenoviral-mediated FHIT 
expression in lung cancer cell line NCI-H460. Among the reg-
ulated genes, a striking percentage fell into functional classes 
relating to cell cycle control, and detailed analysis of this pat-
tern revealed consistent overlap with p53-regulated genes. 
Starting from these preliminary findings, we then tested 55 
surgically resected primary lung cancers and paired normal 
lung tissues and show here that inactivation of both FHIT and 
p53 results in a specific transcriptional phenotype also in a 
clinical setting.
MATERIALS AND METHODS
Cell Lines and Vectors
NCI-H460 (non-small cell lung cancer, NSCLC) and 
HEK-293 cell lines were obtained from American Type Culture 
Collection and cultured in RPMI medium supplemented with 
10% fetal calf serum. Normal human bronchial epithelial 
(NHBE) cells (Clonetics) were cultured in bronchial epithe-
lial growth medium without retinoic acid according to manu-
facturer’s instructions (Lonza). HBEC-KT cells, bronchial 
epithelial cells immortalized with hTERT and CDK4 exoge-
nous expression,18 were obtained from Prof. J. Minna (UTSW, 
Dallas, TX). Stable transfectants of Calu-1 lung cancer cells 
expressing FHIT or p53 under the control of an ecdysone-in-
ducible promoter (Invitrogen) were obtained from Prof. Pier 
Giorgio Petronini (University of Parma, Italy) and have been 
previously described and characterized.7,13 Construction of the 
adenoviral vectors carrying a FHIT or a LacZ control trans-
gene (Ad-FHIT and Ad-LacZ) has been reported elsewhere.5 
For RNAi experiments, we used either oligofection with in 
vitro synthesized siRNAs (Silencer siRNA Construction Kit, 
Ambion) or transfection with plasmids containing siRNA hair-
pin inserts (pSilencer 2.0 U6, Ambion). Stable downregulation 
of FHIT transcript in HBEC-KT cells was achieved with a ret-
roviral vector based on the pSuper backbone (oligoEngine). 
For all the experiments, the target sequence on the FHIT tran-
script was 5-ACCTGTGGTACCAGGACAT-3, and a scram-
bled sequence was used as control.
Chip Hybridization
RNA was extracted 48 hours after infection from NCI-
H460 lung cancer cells transduced with Ad-FHIT or Ad-LacZ 
at a multiplicity of infection of 10. These conditions were 
selected to achieve efficient FHIT expression at the protein 
level without excessive unphysiological overexpression and 
to avoid possible confounding effects on the transcriptome 
deriving from secondary changes induced by prolonged 
transgene expression. Three independent infections were per-
formed, and RNA preparations were pooled, transcribed into 
cDNA, labeled, and hybridized following the manufacturer’s 
protocol to the oligonucleotide microarray Human GeneChip 
HG-U95Av2 (Affymetrix) which contains probes for about 
12,000 genes. To control for experimental variations, two sep-
arate chip hybridizations were carried out both for Ad-FHIT 
and Ad-LacZ RNA harvests. FHIT-mediated induction/
repression was evaluated for each gene by calculating the 
ratio of fluorescence intensity between Ad-FHIT-infected cells 
and Ad-LacZ-infected cells in the four different hybridization 
experiments as follows: FHIT1/LacZ1, FHIT1/LacZ2, FHIT2/
LacZ1, and FHIT2/LacZ2. The median value was employed 
as an index for FHIT-mediated regulation. The whole proce-
dure was repeated twice (starting from thawing of new aliquot 
of NCI-H460 cells) resulting in two independent experiments 
(experiments 1 and 2).
Microarray Data Analysis
The statistical algorithms run by Microarray Suite 5.0 
(MAS 5.0, Affymetrix) were used for monitoring GeneChip 
expression data. Using standard statistical techniques, these 
algorithms generate a file containing an evaluation of the gene 
expression level in the form of qualitative and quantitative val-
ues. The output of MAS 5.0 statistical algorithms (*.CHP file) 
was analyzed using software developed by FIRC Institute of 
Molecular oncology personnel (Milan, Italy) which allows effi-
cient analysis of Affymetrix gene expression data performed in 
replicate, through definition of analysis schemes, data normal-
ization, t test/analysis of variance, and Change-Fold Change-
analysis, and yields lists of differentially expressed genes with 
high confidence.19 The analysis of biological pathways affected 
by FHIT expression was performed with MAPPFinder, an 
accessory program that works with GenMAPP (www.gen-
mapp.org) and the annotations from the Gene ontology (Go) 
Consortium to identify global biological trends in gene expres-
sion data.20 MAPPFinder relates microarray data meeting a 
user-defined criterion for a “significant” change to each term in 
the Go hierarchy, calculating the percentage of genes changed 
for each Go biological process, cellular component, and 
molecular function term. MAPPFinder then calculates a cumu-
lative total of genes changed for a parent Go term and all of its 
children and a statistical score, giving a complete picture of the 
gene expression changes associated with a particular Go term. 
The statistical rating of the relative gene expression activity in 
each Go term is provided as a standardized difference score (z 
score) using the expected value and SD of the number of genes 
meeting the criterion on a Go term under a hypergeometric 
distribution. The z score is useful for ranking Go terms by their 
relative amounts of gene expression changes. For MAPPFinder 
analysis, we selected a criterion relying on MAS 5.0 difference 
calls that allowed comparison of a similar number of changed 
genes for the two different microarray experiments. Grouping 
of genes into functional classes was performed with tools 
available from the NetAffx analysis center (www.affymetrix.
com) and the DAVID bioinformatics resources (http://david.
abcc.ncifcrf.gov/home.jsp).
Real-Time Polymerase Chain Reaction 
Validation
one microgram of RNA obtained from cells infected 
with Ad-FHIT or Ad-LacZ was reverse transcribed into cDNA 
using ImProm-II Reverse Transcription System (Promega). 
All the experiments were run on a GeneAmp 5700 or 7900 
Sequence Detection System using TaqMan technology 
(Applied Biosystems). Primers and probes for the different 
genes were available as ready to use Assays-on-Demand. To 
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establish the optimal cDNA concentration for precise quanti-
fication of the genes, three different dilutions were automati-
cally dispensed in 96-well plates and frozen until needed for 
the polymerase chain reaction (PCR) reaction. Real-time PCR 
was carried out in triplicate in a 50 l volume, and assays 
were repeated on different dilutions as needed. Four different 
endogenous controls (18S, RNAseP, HPRT, and TBP) were 
used as references to normalize the different samples and for 
relative quantification of gene expression. Data were analyzed 
by the comparative Ct method (Ct).
Synchronization
NCI-H460 cells were arrested in S-phase by a double 
thymidine block. Cells were incubated for 24 hours with 2 
mM thymidine, released for 16 hours by washing out the thy-
midine, and then blocked again for 24 hours to arrest cells 
at the beginning of S phase. Lysates were prepared every 
2 hours after final release from thymidine. Cells were also 
synchronized by arresting them at the G
1
/S border with 2 
mM thymidine for 24 hours, followed by a 12 hours release, 
and then arrested at mitosis with nocodazole (100 ng/ml) for 
12 hours. The cells were released from the nocodazole block 
with two washes of fresh medium and allowed to progress 
through G
1
 and into S phase. Distribution of synchronized 
cells in the cell cycle was monitored by flow cytometry analy-
sis of propidium-iodide–stained cells.
Patients and Samples
For molecular studies, 55 tumor lung specimens and 
50 paired nontumor lung tissues were obtained from patients 
undergoing surgical resection at Fondazione IRCCS Istituto 
Nazionale Tumori (Milan, Italy). Among the 55 patients, 43 
(78%) were male and 12 (22%) were female with age ranging 
from 49 to 83 years (median, 66 years). Tumor samples were 
classified according to the latest World Health organization 
histological classification as adenocarcinoma, 37 (67%); 
squamous cell carcinoma, 12 (22%); and other histological 
subtype, 6 (11%). Fresh tissue from tumors and noncancer 
fragments from surrounding lung tissue was immediately 
snap-frozen in liquid nitrogen and stored at –80C until RNA 
isolation. Paraffin-embedded specimens for the immuno-
histochemical studies of FHIT and p53 were also available. 
All samples were collected following the Institution Review 
Board guidelines.
Immunohistochemistry
Immunohistochemical analysis was performed on for-
malin-fixed paraffin-embedded samples using the UltraVision 
detection system (Laboratory Vision Corporation). Antibodies 
used were polyclonal rabbit anti-FHIT (ZR44, Zymed, dilu-
tion 1:400) and mouse anti-human p53 (Do-7, Ylem, dilution 
1:400). p53 immunostaining was classified according to both 
intensity and percentage of positive cells as negative (normal) 
when no staining was present and as positive (indicating sta-
bilization of mutated protein21,22) when staining was detected 
in more than 10% of the cells.
FHIT immunoreactivity was classified according to a 
score obtained by multiplying two parameters: the percentage 
of positive cells (from 0 to 100) by the staining intensity 
mean level (from 0 to 3) for a global score of 0 to 300: score 
0: 0 (negative), score 1: 0 to 50 (weak negative), score 2: 50 
to 200 (weak positive), and score 3: more than 200 (posi-
tive). Normal bronchial and alveolar epithelial cells, taken 
as internal controls, display a strong FHIT expression score 
200 (score 3); extensive loss of FHIT expression is con-
sidered for tumors with scores 50 (score 1); and reduced 
protein expression for scores 50 to 200 (score 2). For statis-
tical comparisons, classes 0–1 and 2–3 were grouped and 
recoded as 0 and 1.
Expression Analysis in Tumor Samples
Real-time PCR analysis was performed with TaqMan-
based technology using readymade assays (Applied 
Biosystems) on a 7900 HT Real-Time PCR System. For each 
target gene, fold change in expression level was evaluated 
using a calibrator and a normalization factor resulting from 
the analysis of five housekeeping genes (ACTB, GAPDH, 
TBP, HPRT, and B2M). Normalization factor to measure the 
expression values for the candidate genes was obtained apply-
ing the geNorm algorithm.23
The analysis from raw data was carried out with differ-
ent approaches. (i) For comparisons between tumor and normal 
samples, normalized expression values of tumor and normal 
samples were averaged for each gene, and t test was calcu-
lated in an independent manner from FHIT and p53 status. 
(ii) For comparisons among tumors, expression values from each 
tumor were normalized using its normal paired tissue or using 
the minimum expressor as calibrator. Results were expressed as 
the median in expression level of samples carrying inactivation 
of both genes (class 0) relative to the median in expression level 
of other classes (class 1), and t test (two-tailed) was calculated. 
Data were also entered in contingency tables using geometric 
means as cutoff to define low and high expressors. The p value 
was evaluated with the Fisher’s exact test. For all analyses, p val-
ues less than 0.05 were considered to be statistically significant.
RESULTS
Microarray Analysis of Fhit-Regulated Genes
To investigate the transcriptional response underlying 
FHIT oncosuppressive function, we selected NCI-H460 lung 
cancer cells, previously shown to be responsive to restora-
tion of FHIT expression both with plasmid24 and adenoviral 
vectors,5 with ensuing slowing of cycling properties, induc-
tion of apoptosis, and reduced in vivo tumorigenicity. Time-
course experiments also revealed that the adenoviral vector 
carrying FHIT cDNA (Ad-FHIT) induced efficient transgene 
already detectable at the protein level 12 hours after infec-
tion, increasing at 24 hours and then remaining stable over 
5 days.14 To evaluate early transcriptional effect, cells were 
harvested 48 hours after infection and RNA extracted for oli-
gonucleotide microarray analysis. We performed two sepa-
rate experiments (with two replicates for each treatment) and 
used for following validation studies a complete list of the 
results of the different analyses (Supplemental Table 1, http://
links.lww.com/JTo/A205), because it has been reported that 
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pooling samples in microarray experiments where the biological 
variability is expected to be small might not be helpful and 
could even decrease one’s ability to identify differentially 
expressed genes.25
The first observation was that under the reported condi-
tions only a small number of transcripts were influenced by 
FHIT restoration, providing highly focused information on 
the affected biological processes: 148 regulated probe sets 
were identified in the first experiment (50 upregulated and 98 
downregulated) and 39 in the second (11 upregulated and 28 
downregulated). The probe sets corresponding to the FHIT 
transcript acted as internal positive control and, as expected, 
were among the upregulated genes in both experiments. Even 
though the perturbation of the transcriptome was small, it 
is noteworthy that seven transcripts (including FHIT) were 
detected as altered in both experiments: in particular, common 
changes included downregulation of kinesin family member 11 
(KIF11) and DNA topoisomerase II (TOP2A) and upregulation 
of cyclin-dependent kinase inhibitor 1A (CDKN1A, p21waf1). 
Regulation of ToP2A and CDKN1A was also confirmed at 
the protein level and had also been previously described in 
other experimental systems.7,14
By combining the results of the different experi-
ments, we obtained a list of 160 FHIT-responsive genes 
(Supplemental Table 1, http://links.lww.com/JTo/A205) 
and selected 28 genes for validation with quantitative real-
time PCR. The results obtained by microarray hybridiza-
tion were confirmed for 25 of 28 (89%) genes analyzed. 
Furthermore, there was a good correlation between the rela-
tive changes in transcript concentration detected using the 
two different techniques (Table 1). During the validation 
phase, we also evaluated the effects of overexpressing FHIT 
in NHBE cells: interestingly, 15 of the 25 (60%) genes vali-
dated by quantitative real-time PCR were also regulated in 
this system in the same manner as FHIT-transduced NCI-
H460 lung cancer cell line, indicating that a similar set of 
genes is regulated at early stages also in nontransformed 
human cells.
TABLE 1. Real-Time PCR Validation of Selected FHIT-Modulated Genes
Gene  
Symbol
Mean Fold Change in 
Microarray Experiments
Real-Time PCR 
Results (Ct) Gene Ontology Biological Process Term
ToP2Aa –2.83 –2.38 (2.63–2.17) DNA replication; response to DNA damage stimulus; chromosome 
segregation
KIF11a –2.64 –2.22 (2.33–2.08) Microtubule-based movement; mitotic spindle organization and biogenesis
NDC80a –2.58 –2.63 (2.94–2.32) Mitotic sister chromatid segregation; spindle organization and biogenesis
KIF2Ca –2.50 –2.34 (2.82–1.94) Microtubule-based movement; establishment and/or maintenance of 
microtubule cytoskeleton polarity
PLK1a –2.10 –2.95 (3.47–2.50) Regulation of progression through cell cycle
CDC6 –2.09 –2.43 (2.95–2.01) DNA replication checkpoint; regulation of cyclin-dependent protein kinase 
activity
CCNA2 –1.98 –2.85 (3.33–2.50) Regulation of progression through cell cycle; mitotic cell cycle G2/M 
transition DNA damage checkpoint
HMGB2 –1.93 –1.89 (1.96–1.82) DNA replication; DNA unwinding during replication; DNA repair; 
nucleosome assembly
BUB1Ba –1.86 –2.14 (2.55–1.79) Spindle organization and biogenesis; mitotic cell cycle checkpoint
BUB1a –1.84 –1.85 (2.17–1.61) Mitosis; mitotic cell cycle spindle assembly checkpoint
CENPFa –1.74 –2.33 (2.43–2.22) G2 phase of mitotic cell cycle; chromosome segregation; kinetochore 
assembly
CDC2a –1.71 –2.35 (2.50–2.21) Regulation of progression through cell cycle
PKMYT1 –1.70 –2.22 (2.44–2.02) Regulation of cyclin-dependent protein kinase activity
MCM5 –1.63 –2.27 (2.43–2.11) Regulation of progression through cell cycle; DNA replication
MCM2 –1.58 –2.04 (2.33–1.79) DNA replication; DNA unwinding during replication
CCNB1a –1.57 –1.84 (2.05–1.64) Regulation of progression through cell cycle; G2/M transition of mitotic cell 
cycle
CCNB2a –1.52 –2.09 (2.40–1.82) Regulation of progression through cell cycle
HMMRa –1.32 –1.77 (2.13–1.47) Cell motility
GDF15a +1.93 +1.77 (1.64–1.91) Transforming growth factor beta receptor signaling pathway
NR4A1 +1.90 +1.64 (1.50–1.79) Regulation of transcription, DNA-dependent; signal transduction
TNFSF9 +1.57 +1.20 (1.08–1.33) Apoptosis; cell proliferation
CDKN1Aa +1.48 +1.63 (1.39–1.91) Regulation of progression through cell cycle; response to DNA damage 
stimulus; negative regulation of cell proliferation
BTG2 +1.34 +1.42 (1.24–1.62) DNA repair; regulation of transcription, DNA-dependent
E2F5a +1.26 +1.26 (1.18–1.34) Regulation of progression through cell cycle; regulation of transcription, 
DNA-dependent
a Regulated also in Ad-FHIT-transduced NHBE.
PCR, polymerase chain rection.
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Synchronization
It has been reported that many of the genes identified 
as differentially expressed in microarray experiments con-
ducted comparing tumor samples with normal tissues have 
a cell cycle-dependent expression, and their apparent regu-
lation might therefore simply reflect the different prolifera-
tive state of the cells being compared and their distribution 
in the phases of the cell cycle.26 As we had previously noticed 
that FHIT restoration in NCI-H460 cells results in slowing of 
cycling properties,5 we analyzed periodicity of expression of 
regulated genes in synchronized NCI-H460 cells to exclude 
that the observed regulations induced by FHIT could merely 
result from changes in the cell cycle distribution. Under 
the transduction conditions used for the microarray experi-
ment, there are no major effects on the cell cycle distribution 
with the only notable effect being a modest reduction in the 
S-phase and an increase in the G2 phase (data not shown). To 
investigate the cell cycle-dependent expression of some of the 
target genes, NCI-H460 cells were synchronized using either 
thymidine-nocodazole or a double-thymidine block. Different 
time-course experiments were performed, and distribu-
tion of the cells was observed using propidium-iodide 
staining and flow cytometry analysis. After confirmation 
of successful synchronization, mRNA was extracted at 
different time points chosen to be representative of increased 
cell distribution in the different phases of the cell cycle 
(Figure 1A). Using unsynchronized cells as reference, the 
changes in expression levels during transit in the different 
phases of the cell cycle could be quantified and the maximum 
fold change could be estimated from the values observed at the 
time points representing complete G1/S or G2/M block. Real-
time PCR analysis revealed periodicity of expression related 
to the cell cycle for many of the genes analyzed, as previously 
reported for other cell lines.26 In particular, we observed G1/S 
increased expression for CDC6, CDKN1A, and KIF11, while 
AURKB, BUB1, CCNA2, CCNB1, CCNB2, and MCM2 were 
predominantly expressed in G2/M, and CENPF, NR4A1, and 
PKMYT1 expression was not cell cycle-dependent. In this 
system, the strongest regulations observed were for CCNB1 
and CCNB2, whose expression increased in G2 by a factor of 
FIGURE 1. Analysis of cell 
cycle-dependent expression of 
selected FHIT-regulated genes. 
Synchronization of NCI-H460 cells 
was used to evaluate periodicity of 
expression. A, Cells were arrested 
in S-phase using a double thymi-
dine block and cell synchrony was 
monitored by flow cytometry of 
propidium-iodide–stained cells. 
The number of cells is plotted 
against DNA content for different 
time points: upon release from 
thymidine, most cells were blocked 
in S-phase, then progressed into 
G2 phase (0–5 hours) and finally 
reentered in G1 phase after 10 
hours (upper panel). Cells were 
also arrested first with thymidine 
and then with nocodazole to 
obtain G2/M block (lower panel). 
B, Real-time PCR analysis of CCNB2 
expression after synchronization 
using either double thymidine or 
nocodazole block showing periodic-
ity of expression of this gene in rela-
tion to cell cycle distribution with 
predominant expression in G2/M 
phase.
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TABLE 2. MAPPFinder Results for Genes Regulated in Ad-FHIT vs. Ad-LacZ Treated Cells














278 Mitotic cell cycle 90 236 354 38.1 66.7 13.18
6259 DNA metabolism 90 332 614 27.1 54.1 9.26
74 Regulation of cell cycle 68 286 357 23.8 80.1 6.75
16043 Cell organization and biogenesis 63 359 631 17.5 56.9 3.79
67 DNA replication and chromosome cycle 54 134 225 40.3 59.6 10.66
6974 Response to DNA damage stimulus 42 161 237 26.1 67.9 5.96
84 S phase of mitotic cell cycle 41 106 187 38.7 56.7 8.93
280 Nuclear division 38 106 141 35.8 75.2 8.01
6281 DNA repair 37 139 204 26.6 68.1 5.73
7067 Mitosis 35 85 111 41.2 76.6 8.72
87 M phase of mitotic cell cycle 35 87 114 40.2 76.3 8.54
7001 Chromosome organization and biogenesis 23 111 224 20.7 49.6 3.13
6261 DNA-dependent DNA replication 21 60 80 35.0 75.0 5.80
910 Cytokinesis 21 64 95 32.8 67.4 5.43
6325 Establishment and/or maintenance of 
chromatin architecture
19 85 192 22.4 44.3 3.21
8380 RNA splicing 17 71 97 23.9 73.2 3.36
86 G2/M transition of mitotic cell cycle 15 35 44 42.9 79.5 5.89
6333 Chromatin assembly/disassembly 15 50 120 30.0 41.7 4.17
7017 Microtubule-based process 15 57 124 26.3 46.0 3.57
82 G1/S transition of mitotic cell cycle 14 44 53 31.8 83.0 4.29
79 Regulation of CDK activity 13 30 38 43.3 78.9 5.53
75 Cell cycle checkpoint 13 30 34 43.3 88.2 5.53
6334 Nucleosome assembly 12 27 80 44.4 33.8 5.43
7050 Cell cycle arrest 11 39 55 28.2 70.9 3.33
7088 Regulation of mitosis 10 18 25 55.6 72.0 5.92
7059 Chromosome segregation 9 17 21 52.9 81.0 5.41
6129 Protein-disulfide reduction 8 18 44 44.4 40.9 4.43
6302 Double-strand break repair 7 13 14 53.8 92.9 4.83
42773 ATP synthesis coupled electron transport 7 17 43 41.2 39.5 3.88
6120 Mitochondrial electron transport 6 15 36 40.0 41.7 3.50
6270 DNA replication initiation 6 16 22 37.5 72.7 3.30
7093 Mitotic checkpoint 5 9 13 55.6 69.2 4.18
30261 Chromosome condensation 5 11 13 45.5 84.6 3.57
90 Mitotic anaphase 5 11 12 45.5 91.7 3.57
72 M-phase specific microtubule process 5 12 16 41.7 75.0 3.31
9262 Deoxyribonucleotide metabolism 4 4 13 100.0 30.8 5.59
7051 Spindle assembly 4 8 11 50.0 72.7 3.45
Experiment 2
6259 DNA metabolism 56 332 614 16.9 54.1 2.39
6412 Protein biosynthesis 51 310 597 16.5 51.9 2.09
278 Mitotic cell cycle 48 236 354 20.3 66.7 3.64
16070 RNA metabolism 33 186 297 17.7 62.6 2.14
6396 RNA processing 31 168 273 18.5 61.5 2.31
6281 DNA repair 26 139 204 18.7 68.1 2.19
87 M phase of mitotic cell cycle 23 87 114 26.4 76.3 3.91
280 Nuclear division 23 106 141 21.7 75.2 2.84
7067 Mitosis 22 85 111 25.9 76.6 3.71
6397 mRNA processing 22 104 137 21.2 75.9 2.65
8380 RNA splicing 17 71 97 23.9 73.2 2.89
398 Nuclear mRNA splicing, via spliceosome 16 68 86 23.5 79.1 2.73
6512 Ubiquitin cycle 13 55 128 23.6 43.0 2.47
165 MAPKKK cascade 8 32 39 25.0 82.1 2.12
(Continued)
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3 (Figure 1B). The downregulation observed after FHIT 
expression restoration does not therefore seem to depend 
on changes in cell cycle distribution. overall, the changes 
observed confirmed cell cycle-regulated expression in 9 of 
12 genes tested, but the extent of the regulation detected in 
microarray experiments was compatible with a direct tran-
scriptional change induced by the FHIT protein.
Pathway Analysis and Link with p53
To identify which biochemical pathways are altered after 
FHIT modulation, we employed MAPPFinder analysis which 
provides indication on the relative enrichment in a particular 
dataset of transcripts involved in specific cellular processes. 
Similar pathways were affected in the two different experi-
ments: in particular, a very high percentage of the regulated 
genes clustered in pathways related to cell cycle (such as mito-
sis, control of cell cycle, and chromosome segregation), DNA 
replication, and cell proliferation, highlighting the tumor sup-
pressor activity of FHIT at the transcriptional level (Table 2).
The 160 genes identified as FHIT-modulated were clas-
sified into functional groups using different bioinformatics 
tools. All the known genes were easily grouped into promi-
nent functional classes with striking prevalence of processes 
such as cell cycle regulation, DNA replication and synthesis, 
chromosome and mitosis, and transcription and growth fac-
tor-related signaling. The most represented function was cell 
cycle (Go ID 7049) with 43 genes (p = 1.06 E-21), and in 
particular M phase (Go ID 87) with 23 genes (p = 2.05 E-17). 
There was specific evidence of regulation of genes involved 
in chromosome segregation (Go ID 7059, six genes, p = 3.20 
E-05) and in spindle organization and biogenesis (Go ID 
7051, six genes, p = 1.48 E-06). Twelve genes were apoptosis-
related (Go ID 6915, p = 0.0226). one was a growth factor 
inhibitor of the TGF-beta superfamily (GDF15, also known as 
PLAB, placental bone morphogenetic protein). Interestingly, 
this growth factor inhibitor is a secreted protein, suggesting 
that there could be a paracrine mechanism by which FHIT 
might exert its tumor suppressive effects on adjacent, neigh-
boring tumor cells. Two repressed genes, DNA topoisomerase 
II (TOP2A) and thymidylate synthase (TYMS), grouped in 
DNA replication and synthesis, are also determinants of drug 
resistance and their inhibition induces apoptosis.
The experimental conditions were set to identify early 
response genes because RNAs were prepared from cells 
harvested 48 hours after infection, a time point at which no 
visible signs of apoptosis are evident whereas a G2/M block 
can already be detected.5 The experimental design therefore 
explains the very high percentage of genes related to cell cycle 
control together with the initial involvement of apoptosis-re-
lated genes.
Interestingly, several of the genes identified as FHIT-
regulated are common with those identified as p53 regulated 
by early microarrays experiments,15,16 indicating that the 
two genes might have interconnected pathways as suggested 
also by other experimental evidence.12,13 We have also pre-
viously shown that FHIT and p53 independently increase 
p21waf1 levels and that their coexpression has synergistic 
oncosuppressive effect on lung cancer cell line Calu-1.13 
The list of genes found in our experiments was therefore 
compared with those recently reported as p53 downregu-
lated in experiments designed to identify repression of cell 
cycle regulatory and growth promoting genes.27,28 The over-
lap among these highly focused lists was 40%, and six genes 
were common to all three: CCNA2, CDC20, MCM6, MCM7, 
UBE2C, and TPX2.
In conclusion, the collected data demonstrate that the 
FHIT gene is involved in regulation of various critical cel-
lular processes in accordance with its oncosuppressive func-
tion and that several of the cell cycle regulatory genes whose 
expression is altered after FHIT restoration seem to be also 
controlled by p53.
RNAi in NHBE and HEK-293
To evaluate how modulation of FHIT levels might influ-
ence other cell types, RNAi technology was used to reduce 
endogenous FHIT expression in NHBE and in HEK-293 
cells. Different sequences for silencing using transfection 
with oligonucleotide duplexes were evaluated to select those 
that consistently led to downmodulation of the transcript 
(Figures 2A, B). The reduction obtained by siRNA transfec-
tion was also quantified by real-time PCR which confirmed 
TABLE 2. (Continued)













6096 Glycolysis 8 32 55 25.0 58.2 2.12
7059 Chromosome segregation 6 17 21 35.3 81.0 2.82
187 Activation of MAPK 5 12 16 41.7 75.0 3.04
72 M-phase specific microtubule process 5 12 16 41.7 75.0 3.04
19884 Antigen presentation, exogenous antigen 5 12 34 41.7 35.3 3.04
6888 ER to golgi transport 5 15 20 33.3 75.0 2.42
6406 mRNA-nucleus export 4 7 14 57.1 50.0 3.55
7257 Activation of JUNK 3 4 8 75.0 50.0 3.76
8543 FGF receptor signaling pathway 3 7 8 42.9 87.5 2.41
7051 Spindle assembly 3 8 11 37.5 72.7 2.12
a Terms with a z score 2 and at least 3 but less than 100 genes meeting the criterion are shown.
Go, gene ontology, ER, endoplasmic reticulum.
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reduction of the transcript of more than 70% followed by 
a twofold protein reduction. The expression of a subset of 
genes identified in the microarray experiment and involved 
in cell cycle control was then tested by real-time PCR. In 
accordance with data obtained after overexpression of FHIT 
in cancer cells, the downmodulation in nontransformed 
cells led to opposite effects on transcription; in particular, 
we observed upregulation of several genes related to cell 
proliferation. In NHBE cells, 54% of the transcripts tested 
(7/13) was regulated, including CCNB1, KIF11, AURKB, 
and CENPF (Figure 2A). Similar results were also obtained 
in HEK-293 cells (Figure 2B) where FHIT downmodulation 
also resulted in upregulation of transcripts related to cell 
cycle control (CCNA2, CCNB1, CENPF, KIF11, AURKB, 
BUB1, and CDC6). The extent of regulation of the differ-
ent genes was always in the range described for microarray 
and real-time experiments on NCI-H460 cell line, generally 
between 1.5- and 2.5-fold change. This reflects the overall 
fine tuning of biochemical pathways produced by FHIT and 
indicates that loss of function of the FHIT protein in normal 
cells might co-operate in the acquisition of the transformed 
phenotype.
RNAi in HBEC-KT and HBEC-KT p53–
HBEC-KT cells are derived from normal bronchial 
epithelium and have been immortalized with hTERT and 
CDK4. They have epithelial morphology, express p63 and 
cytokeratins 7,14,17,19, and display a transcriptional profile 
similar to nonimmortalized bronchial cells,18 thus represent-
ing a good model to test the effect of stable silencing of FHIT 
in bronchial cells. These cells have also additionally been 
modified to silence p53 expression (p53–) without acquiring 
a transformed phenotype.29 We, therefore, used HBEC-KT 
p53– cells to investigate the interplay between the two path-
ways. Retroviral vectors expressing short hairpin sequences 
targeting the FHIT gene were efficient in downregulating 
the FHIT protein both in HBEC-KT and in HBEC-KT 
p53– (Figure 3A). Silencing of FHIT resulted in changes 
in the expression of genes identified as FHIT-regulated in 
previous experiments including upregulation of CCNB1, 
CCNB2, and KIF11. The transcriptional effects observed 
were higher in HBEC-KT p53–, highlighting once more 
the link between FHIT and p53. The convergence of the 
effects of the two proteins on the same mediators implies 
that loss of both could have additive effects as substantiated 
by higher transcriptional deregulation induced by FHIT loss 
in a p53-deficient background. In particular, FHIT silencing 
was associated to strong down-modulation of CDKN1A only 
in absence of p53 (Figure 3B).
FHIT and p53 Modulation in Calu-1 Lung 
Cancer Cells
To further substantiate the possibility that coopera-
tion at the molecular level between FHIT and p53 is linked 
to common mediators of their antiproliferative effects, we 
selected Calu-1 lung cancer cells which lack endogenous 
expression of both proteins. As previously described, these 
cells were genetically modified with a plasmid ecdysone-
inducible system to obtain stable clones with tightly regu-
lated inducible expression of either protein after addition of 
the ecdysone analog Ponasterone A.7,13 RNA extracted after 
induction of FHIT or p53 was used for real-time PCR on 14 
proliferation-related genes previously identified as regulated 
by both proteins. For most genes (10/14), the same pattern of 
regulation was indeed observed, with both proteins causing 
FIGURE 2. FHIT knockdown regu-
lates proliferation-related genes. 
Normal human bronchial epithelial 
(NHBE) cells (A) and HEK-293 cells 
(B) were transiently transfected 
with FHIT oligo siRNA or control 
siRNA (siGAPDH or siScrambled). 
FHIT expression is reduced in both 
cell lines (A and B, left panels). 
Silencing of FHIT resulted in 
changes in expression of different 
cell cycle-related genes analyzed by 
real-time PCR (A and B, right pan-
els). Expression data are normalized 
on cells transfected with scrambled 
oligo siRNA. Asterisk (*) indicates 
genes whose expression was regu-
lated more than 1.2 fold.
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downregulation of expression of target genes usually in the 
range of 1.5 to 2 fold (Figure 4A).
FHIT and p53 Expression Analysis in NSCLC
Based on the results obtained on the cell cultures, 
we investigated whether the molecular status of FHIT and 
p53 could influence the expression profile of cell cycle-
related genes in 55 surgically resected primary lung can-
cer and paired normal lung tissue. Immunohistochemical 
staining was performed to evaluate the expression of FHIT 
and p53 in formalin-fixed  paraffin-embedded tissue. Loss of 
FHIT protein expression (FHIT–, abnormal) and abnormal 
p53 nuclear protein accumulation (p53–, abnormal) was found 
in 35 of 55 (64%) cases and 36 of 55 (65%) cases, respec-
tively. Considering the combination of the two genes, normal 
pattern of FHIT and p53 was only observed in 7 of 55 (13%) 
samples, the inactivation of either gene in 48 of 55 (86%) 
samples, and inactivation of both genes in 23 of 55 (42%). 
The status of the two genes was not correlated supporting the 
hypothesis of the independence of the two pathways; how-
ever, the frequency of the observed alteration confirms their 
FIGURE 3. Stable down-modulation of FHIT regulates genes involved in cell cycle control in HBEC-KT and HBEC-KT modified 
to silence p53 expression (HBEC-KT p53–). A, Knockdown of FHIT was obtained transducing the cells with a retroviral vector 
carrying a shRNA targeting FHIT transcript (sh-FHIT). A retroviral vector containing a scrambled sequence was used as control 
(SCRAMB). FHIT expression was estimated by Western Blot analysis and was reduced in both cell lines. Actin was used as a 
protein loading control. B, Transcriptional changes in expression of a subset of genes involved in cell cycle control which are 
either upregulated (left) or downregulated (right) in HBEC3KT and HBEC-KTp53– after reduction of FHIT transcript. The results 
are expressed as level of mRNA relative to untransfected control cells.
FIGURE 4. FHIT and p53 status 
impinge upon expression of prolif-
eration-related genes in non-small 
cell lung cancer (NSCLC) cell lines 
and primary tumors. A, Calu-1 lung 
cancer cells stably transfected with 
plasmid constructs driving inducible 
expression of either FHIT (Calu1-
FHIT) or p53 (Calu1-p53) were 
treated with 10 mM Ponasterone 
A for 3 days before RNA extraction 
and real-time PCR analysis. Results  
are expressed as fold change in the  
expression level relative to untreated 
cells. B, Real-time PCR analysis of 
proliferation related genes in 55 
primary NSCLC samples. Results  
are expressed as median expression 
level (6SD) of samples with inactiva-
tion of both FHIT and p53 (FHIT–/
p53–, n = 23) relative to the median 
expression level of samples of other 
groups (n = 36). * p < 0.05 for dif-
ferences between the two groups.
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central role in lung carcinogenesis. To determine whether 
altered levels of both proteins are associated with a specific 
transcription phenotype, samples were grouped for statis-
tical comparison in two classes: class 0 including samples 
with FHIT and p53 abnormal expression (n = 23) and class 1 
including cases with all other combinations of the two genes 
(n = 32). Interestingly, 10 of 26 (40%) early-stage tumors 
(I–II) already carried alteration in expression of both genes 
confirming their involvement in the early phases of lung 
tumorigenesis.
To evaluate whether tumors with inactivation of both 
genes could have a distinctive expression phenotype, we 
selected 16 proliferation-related genes extracted from the 
previous signature and evaluated by real-time PCR their 
expression levels in primary NSCLC. As expected for pro-
liferation markers, most of the target genes were significantly 
differentially expressed between tumors and normal tissue 
(data not shown).
We then analyzed expression levels of these transcripts 
normalizing each tumor sample with its paired normal tis-
sue and observed that 10 of 16 (62%) proliferation-asso-
ciated genes were significantly differentially expressed in 
lung cancer samples with inactivation of both FHIT and p53 
(class 0). In particular, these tumor samples showed altered 
level of expression of BUB1 (p = 0.008), BUB1B (p = 
0.015), CCNB1 (p = 0.049), CDC6, (p = 0.011), CENPF 
(p = 0.017), KIF11 (p = 0.0024), MCM2 (p = 0.039), MCM6 
(p = 0.002), and TOP2A (p = 0.0002) (Figure 4B). Comparable 
results were also obtained by directly comparing tumor 
samples.
In addition, we performed a supplementary analy-
sis after classifying the tumors as low and high expressors 
(using the geometric mean expression value for each gene) 
and evaluating different frequencies of high and low expres-
sors between the two classes of tumors (class 0 and class 1). 
For 12 of 16 (75%) genes, lung cancer samples with inactiva-
tion of both FHIT and p53 had the strongest deregulation of 
expression. In particular, these tumors showed high levels of 
expression of CCNB2 (p = 0.005), CCNA2 (p = 0.011), CDC6 
(p = 0.011), TOP2A (p = 0.001), and CENPF (p = 0.005) and 
low levels of expression of the cell cycle inhibitor CDKN1A 
(p = 0.02).
DISCUSSION
The oncosuppressive properties of the FHIT protein 
have been analyzed in several functional studies that have 
generally shown a potent antitumor effect of the restoration 
of its expression in FHIT-deficient cancer cell lines (reviewed 
by Ishii et al.30). Immunohistochemistry has also revealed 
frequent loss of expression even in preinvasive lesions of 
the lung,3 indicating that FHIT inactivation might represent 
one of the earliest changes during lung cancer development. 
Taken together, these data suggest an important role in trans-
formation, but the precise mechanism of action remains 
unclear. Little is known about interacting proteins, although 
physical interactions with tubulin,31 the ubiquitin-conjugating 
enzyme hUBC9,32 and MDM212 have been reported. FHIT 
has also been implicated in the regulation of crucial cellu-
lar functions, including cell cycle,33 apoptosis,24 and DNA 
repair,10 but its precise role in these different contexts has not 
been fully elucidated. In this study, we have investigated the 
transcriptional changes associated with modulation of FHIT 
expression in different cellular systems. Induced changes 
seemed to be of limited magnitude, suggesting a role in the 
fine tuning of different biological systems. This is in agree-
ment with previous observations showing dose-dependent 
effect of FHIT in cell cycle control13 and with its function in 
the DNA damage response, where it has been proposed that 
inactivation of FHIT contributes to accumulation of abnor-
mal checkpoint phenotypes during cancer development.34 
Furthermore, it has recently been shown that a small and 
transient reduction in FHIT levels contributes to transmis-
sion of mitogenic signals from tyrosine kinase receptors in 
breast cancer cells.8 In several cellular processes, the FHIT 
protein could act as a sensor to influence cell fate following 
different kinds of stimuli, which corroborate with our ini-
tial observation of enhanced sensitivity to external apoptotic 
stimuli in FHIT reexpressing cells.5
In a recent transcriptional analysis of adenoviral-me-
diated FHIT expression in lung cancer, we found regulation 
of multiple components of the Ras/Rho GTPase molecular 
switch.17 Although we did not observe a large fraction of regu-
lated genes associated with this pathway, possibly due to the 
different cellular model and study design, we could detect 
downregulation of the guanine nucleotide exchange factor 
RAPGEF2 (a Ras activator) and of the geranylgeranyl trans-
ferase RABGGTB, confirming a possible involvement of the 
Ras pathway in FHIT-mediated tumor suppression.
Increased levels of FHIT also caused regulation of cell 
cycle control-related genes in NHBE cells indicating that a 
common transcriptional program is activated also in nontrans-
formed human cells. It is possible to speculate that conversely 
a diminished FHIT function in normal cells could create a per-
missive state for (hyper)proliferation, partial insensitivity to 
apoptotic stimuli, and, finally, transformation.
When FHIT and p53 were both downregulated in 
immortalized bronchial cells, the extent of transcriptional 
perturbation was increased, considering both the number 
of regulated genes and the relative expression levels. This 
observation and the considerable overlap between cell cycle-
related genes regulated by FHIT and p53 indicate that the 
two proteins might co-operate in controlling key cellular 
processes. This is highlighted also by the observation that 
the selection of 22 genes associated with cell cycle common 
to p53 and p73 responses described by Scian et al.28 con-
tains nine of the FHIT-regulated genes (41%), and a similar 
overlap (19/45, 42%) was also present in the list of p53-re-
pressed cell cycle regulatory genes found in prostate cancer 
cells infected with Ad-p53.27 Interestingly, the complete set 
of p53-repressed genes of the same study (n = 111) has only 
25% overlap with FHIT-regulated genes (28/111), indicating 
that high similarities in transcriptional changes elicited by 
FHIT and p53 are confined to effects on the cell cycle where 
the two genes might act on common mediators and not to 
other metabolic pathways. Although it has been suggested 
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that synergistic tumor suppression by FHIT and p53 might 
be due to direct effects of FHIT on MDM2 resulting in 
increased p53 levels,12 we have not detected changes in p53 
neither at mRNA or protein level after Ad-FHIT transduc-
tion. Furthermore, the oncosuppressive properties of FHIT 
and the effects on p21waf1 regulation had been previously 
demonstrated also in p53-deleted cell lines,4,7 and some of 
the known p53 targets were regulated in an opposite fashion 
in Ad-FHIT-infected cells (e.g., PCNA was downregulated 
and E2F5 upregulated), indicating that the two pathways 
are largely independent but could converge on common 
mediators.
This crosstalk could be particularly relevant in the con-
text of bronchial cells, because FHIT and p53 inactivation 
are two of the earliest genetic changes observed during the 
development of lung cancer. Both genes have been implicated 
in DNA damage response and apoptosis, and it is therefore 
tempting to speculate that an early inactivation of both pro-
teins could promote the accumulation of further genetic dam-
age or at least create a cellular environment more prone to 
transformation cues.
These findings indicated the need for further extensive 
studies in primary lung cancer specimens, because the identi-
fication of gene alterations associated with different behavior 
in tumors could have great relevance for the translation of 
experimental data in clinical practice. Primary tumors with 
inactivation of both FHIT and p53 had a distinctive expres-
sion pattern indicating a possible distinct phenotype of these 
tumors. Among the most regulated genes of particular inter-
est was ToP2A. We demonstrated in a previous study14 that 
reexpression of FHIT in NCI-H460 cells resulted in reduced 
sensitivity to topoisomerase I and II inhibitors associated to 
a reduced level of the target. on the contrary, in FHIT- and 
p53-negative cases, the increase in TOP2A expression could 
potentially represent a therapeutic target, and inhibitors of 
TOP2A such as doxorubicin could play an important thera-
peutic role.
Interestingly, 50% of early-stage tumors already car-
ried inactivation of both genes suggesting an early role for 
FHIT and p53 loss in lung carcinogenesis. An explanation of 
this aspect could be that the genomic location of the FHIT 
gene on chromosome 3p14.2 is already linked to an intrinsic 
susceptibility of being targeted during carcinogenesis because 
this gene spans FRA3B, the most active of the common frag-
ile sites. Alterations of chromosome 3p are common in many 
cancer of epithelial origin, and it is of particular interest that 
alterations of the FHIT gene are strictly associated with smok-
ing habits of lung cancer patients3,35 and so is the mutational 
spectrum of the p53 gene.36 It is possible to envision a situa-
tion in which carcinogen-mediated inactivation of these two 
genes in bronchial cells would create a preneoplastic state of 
insensitivity to apoptotic signals and error-prone replication, 
thus leading to accumulation of additional genetic damage 
and finally to an overt cancer phenotype.
The signature of FHIT-regulated genes identified in this 
study might prove instrumental in further defining the path-
ways in which this gene is involved to better understand the 
mechanisms underlying bronchial cell transformation. These 
results confirm crosstalk between FHIT and p53 in regulating 
proliferation in lung cancer and suggest a possible distinctive 
phenotype for tumors with inactivation of both genes therefore 
identifying a gene expression pattern that might have potential 
clinical implications.
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